Jeito Capital invests €184 million ($213 million) in Odyssey Therapeutics, a clinical-stage biopharmaceutical company focused on developing precision-targeted treatments for autoimmune and inflammatory diseases.

Information on the Target

Odyssey Therapeutics, founded in 2021 and headquartered in the United States, is a clinical-stage biopharmaceutical company focused on transforming treatment standards for patients suffering from autoimmune and inflammatory diseases. The firm specializes in developing precision-targeted medications aimed specifically at treating these complex conditions. Led by Dr. Gary D. Glick, the company boasts an experienced management team with substantial expertise in drug development and successful biopharmaceutical transactions.

Odyssey has developed significant capabilities in drug discovery and development, establishing its presence in both the U.S. and Europe. Through its proprietary research programs, the company has successfully advanced several drug candidates through various clinical milestones, forming important collaborations with leading pharmaceutical and biotechnology partners.

Industry Overview in the United States

The biopharmaceutical industry in the United States is a dynamic sector characterized by rapid innovation and a strong pipeline of new therapies. With a concentrated focus on addressing unmet medical needs, particularly in autoimmune a